Iomai Corporation (IOMI)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

20 FIRSTFIELD ROAD, SUITE 250 GAITHERSBURG, MD 20878

Iomai Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of vaccines and immune system stimulants. Its products under development include IS patch for pandemic flu program, a Phase 1 clinical trial IS patch that, when used in conjunction with an injectable flu vaccine, is designed to stimulate an immune response, as well as that allows public health officials to extend vaccine supply in the event of an influenza pandemic; and IS patch for elderly receiving flu vaccines, a Phase 2 clinical trial IS patch to improve the immune response of the elderly to existing injectable influenza vaccines. The company also develops a needle-free flu vaccine patch, a Phase 1 clinical trial product candidate, which combines flu antigens with an adjuvant in a single patch; a needle-free pandemic flu vaccine patch, a product candidate under preclinical development, which combines pandemic flu antigen with an adjuvant in a single patch to solve issues regarding mass vaccination in the event of an outbreak of pandemic flu; and a needle-free travelers' diarrhea vaccine patch, a Phase 2 clinical trial product candidate, which is designed to induce a immune response that diminished the severity and delayed the onset of the common form of travelers' diarrhea. Iomai Corporation's vaccines and immune system stimulants are delivered to the skin via a needle-free technology, transcutaneous immunization, a proprietary technology designed to trigger an immune response by targeting Langerhans cells.

View SEC Filings from IOMI instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding IOMI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IOMI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ERCK STANLEY C PRESIDENT & CEO

  • Officer
  • Director
No longer subject to file 2008-08-05 0

GLENN GREGORY M CHIEF SCIENTIFIC OFFICER

  • Officer
No longer subject to file 2008-08-05 0

WILSON RUSSELL P CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2008-08-05 0

DOUGLAS RICHARD

  • Director
No longer subject to file 2008-08-05 0

DOUGLAS R GORDON

  • Director
No longer subject to file 2008-08-05 0

MEYER F WELLER

  • Director
No longer subject to file 2008-08-05 0

VERNON THOMAS MARTIN JR

  • Director
No longer subject to file 2008-08-05 0

NEW ENTERPRISE ASSOCIATES 10 L P

NEA PARTNERS 10 L P

BARRIS PETER J

KRAMLICH C RICHARD

NEWHALL CHARLES W III

PERRY MARK W

SANDELL SCOTT D

TRAINOR III EUGENE A

  • 10% Owner
0 2008-08-04 0

BARRETT M JAMES

  • Director
  • 10% Owner
0 2008-08-04 0

INTERCELL AG

  • 10% Owner
13,384,979 2008-08-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments